89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 48,150 shares of the Company's common stock to four new employees (the "Inducement Grants") on May 6, 2024 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
旧金山，2024 年 5 月 10 日（GLOBE NEWSWIRE）— 专注于开发和商业化治疗肝脏和心脏代谢疾病创新疗法的临床阶段生物制药公司89bio, Inc.（“公司” 或 “89bio”）（纳斯达克股票代码：ETNB）今天宣布，公司董事会薪酬委员会批准向其授予不合格股票期权于2024年5月6日（“授予日期”）向四名新员工共购买48,150股公司普通股（“激励补助金”）。激励补助金是根据公司2023年激励计划（“计划”）发放的。根据纳斯达克上市规则5635（c）（4），激励补助金是作为激励材料发放给这些在89bio工作的个人的。
The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio's common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee's start date, and thereafter the remainder of the shares vest in 12 equal quarterly installments, subject to each employee's continued employment with 89bio through the applicable vesting dates.
激励补助金的每股行使价等于89bio普通股在授予日的收盘价。激励补助金将在四年内归属，其中 25% 的股份将在员工入职一周年之际归属，此后，其余股份将分12次等额分季度归属，前提是每位员工在适用的归属日期之前继续在89bio工作。
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
关于 89bio
89bio是一家临床阶段的生物制药公司，致力于为缺乏最佳治疗选择的肝脏和心脏代谢疾病患者开发一流的疗法。该公司专注于通过治疗代谢功能障碍相关性脂肪肝炎（MASH）和严重高甘油三酯血症（SHTG）的临床开发，快速推进其主要候选药物pegozafermin的发展。Pegozafermin 是一种专门设计的、可能是同类最佳的成纤维细胞生长因子 21 (FGF21) 类似物，采用独特的糖聚合技术，可通过延长半衰期来优化生物活性。该公司总部位于旧金山。欲了解更多信息，请访问 www.89bio.com 或者关注公司 领英.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
投资者联系人：
张安妮
89bio, Inc.
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
PJ Kelleher
LifeSci 顾问有限公司
+1-617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
媒体联系人：
Sheryl Seapy
真正的化学
sseapy@realchemistry.com
译文内容由第三方软件翻译。